drugset / Trial / NCT04272333

Intratumoral Microdosing of Motolimod in HNSCC

NCT04272333

NaSingle-groupOpen-labelBasic science

Summary

This is a multi-center, single arm, open-label, multi-agent, localized pharmacodynamic biomarker Phase 0 trial designed to study the biological effects within the tumor microenvironment of motolimod and motolimod combined with nivolumab when administered intratumorally in microdose quantities via the CIVO device in patients with head and neck squamous cell carcinoma (HNSCC). CIVO stands for comparative in vivo oncology.

Timeline

Start
2021-10-15
Primary completion
2022-03-25
Completion
2022-03-25

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Motolimod Small molecule Other
Subject Nivolumab Monoclonal antibody Other